Welcome to our dedicated page for Generation Bio Co. news (Ticker: GBIO), a resource for investors and traders seeking the latest updates and insights on Generation Bio Co. stock.
Generation Bio Co. (NASDAQ: GBIO) is a Cambridge, Massachusetts-based biotechnology company that reports focusing on T cell-driven autoimmune diseases using genetic medicine approaches. Its news flow provides insight into the progress of its cell-targeted lipid nanoparticle (ctLNP) platform, siRNA programs, corporate strategy and capital markets activity.
Company press releases highlight research updates on its ctLNP system, including non-human primate data showing selective delivery of siRNA to T cells and knockdown of specific molecular targets. News items also describe the development of lead siRNA candidates aimed at upstream regulators of T cell activation, proliferation and differentiation, reflecting the company’s emphasis on modulating autoreactive T cells in vivo.
Investors and followers of GBIO can also find regular financial results coverage, where Generation Bio reports quarterly cash balances, research and development spending, general and administrative expenses and net loss figures. These updates often include commentary on strategic priorities, cash runway expectations and one-time items such as lease-related settlements.
In addition to scientific and financial updates, Generation Bio’s news includes corporate and strategic developments. During 2025, the company announced a review of strategic alternatives, a significant restructuring of its workforce, leadership transitions in the chief executive role and a 1-for-10 reverse stock split intended to support continued Nasdaq listing. Later in the year, the company disclosed an Agreement and Plan of Merger with XOMA Royalty Corporation involving a tender offer and planned merger.
This news page aggregates these disclosures, allowing readers to follow Generation Bio’s research progress, strategic decisions and transaction-related announcements over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Generation Bio (Nasdaq:GBIO) has announced that CEO Geoff McDonough, M.D., will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 18th at 3:00 p.m. EST. Investors can access a live webcast on the company's investor website, with a replay available for 30 days after the event.
Generation Bio specializes in genetic medicines aimed at providing sustainable, redosable treatments for both rare and common diseases. Their innovative platform utilizes a unique non-viral genetic medicine, featuring closed-ended DNA (ceDNA) and a specialized delivery system known as cell-targeted lipid nanoparticles (ctLNP). This technology is designed to enable long-lasting treatment effects from a single dose and has the potential to significantly scale up production.
Generation Bio Co. (Nasdaq:GBIO) has appointed Yalonda Howze, J.D., as its chief legal officer and secretary. Howze brings nearly two decades of legal experience in biotechnology and life sciences, having previously served at Codiak BioSciences and as a partner at Mintz Levin. CEO Geoff McDonough expressed optimism about her contributions to the company’s ambitious goal of developing transformative genetic medicines for rare and prevalent diseases. Generation Bio focuses on innovative genetic therapies using its proprietary non-viral delivery system, aiming for long-lasting and adjustable treatments.